Insider Transactions Reported by 22 Insiders of Recursion Pharmaceuticals, Inc.

Symbol
RXRX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
Salt Lake City, UT

Insiders trading volume in the past year

Recursion Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Lux Ventures IV, L.P. Former 10% Owner $138M Dec 7, 2021
Mubadala Investment Co PJSC 10%+ Owner $137M Mar 2, 2023
Zachary Bogue Director, 10%+ Owner $39.5M Jul 3, 2023
Blake Borgeson Director $30M -$961K -3.1% Dec 2, 2025
Dean Y. Li Director $15.6M Oct 1, 2025
MIC Capital Partners (Public) Parallel Cayman, LP 10%+ Owner $14.7M Nov 1, 2021
Michael Secora Chief Financial Officer $9.19M Nov 15, 2024
Christopher Gibson Chief Executive Officer, Director $3.96M -$8.13M -67.3% Dec 4, 2025
Ben R. Taylor Chief Financial Officer $3.18M Nov 25, 2025
Tina Marriott President and COO $3.13M Nov 15, 2024
Najat Khan Chief R&D Commercial Officer, Director $3.05M -$202K -6.23% Nov 17, 2025
Shafique Virani Chief Business Officer $1.45M Jan 16, 2024
David J. Mauro Chief Medical Officer $1.39M Nov 15, 2024
Ramona Doyle Chief Medical Officer $1.28M May 16, 2022
Zavain Dar Director $673K Oct 1, 2025
Franziska Michor Director $565K Jun 18, 2025
Chavez R. Martin Director $530K Apr 1, 2024
Terry-Ann Burrell Director $514K Jul 1, 2024
Robert Hershberg Director $328K Jun 18, 2025
Namandje Bumpus Director $212K Jun 18, 2025
Elaine D. Sun Director $212K Jun 18, 2025
Mic Capital Partners (Public) (Us) Im, Llc Other* Nov 1, 2021

Recent Insider Transactions by Companies or Individuals for Recursion Pharmaceuticals, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.